PLOD2 Is a Prognostic Marker in Glioblastoma That Modulates the Immune Microenvironment and Tumor Progression

Nina Kreße(Otto-von-Guericke-Universität Magdeburg), Claudia A. Dumitru(Otto-von-Guericke-Universität Magdeburg)
International Journal of Molecular Sciences
May 27, 2022
10.3390/ijms23116037
Cited by 18

Related Papers

Neutrophils Activate Tumoral CORTACTIN to Enhance Progression of Orohypopharynx Carcinoma
|Frontiers in Immunology|2013|30
Progesterone Receptor Membrane Component 1 (PGRMC1) Modulates Tumour Progression, the Immune Microenvironment and the Response to Therapy in Glioblastoma
|Cells|2023|11
The Roles of AGTRAP, ALKBH3, DIVERSIN, NEDD8 and RRM1 in Glioblastoma Pathophysiology and Prognosis
|Biomedicines|2024|2